Label (71610 0939 89)
Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 71610-939
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 71610-939). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Aphena (Aphena)
Figure-1 (Sacubitril Valsartan Figure 1)
This text presents a list of coadministered drugs along with their geometric mean ratio and 90% CI. The drugs listed include Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HerTZ, Metformin, Atorvastatin, and Sildenafil, with their respective values indicated. The text also mentions a change relative to reference for each drug.*
Figure-2 (Sacubitril Valsartan Figure 2)
Sacubitril-valsartan-figure-3.jpg (Sacubitril Valsartan Figure 3)
This is a comparison of the time to first occurrence of cardiovascular (CV) death or heart failure hospitalizations between two treatments, Sacubitril and Valsartan versus Enalapril, conducted in the PARADIGM-HF study. The data shows a statistically significant difference (p<0.0001) favoring Sacubitril and Valsartan in reducing the risk of CV death or heart failure hospitalizations. Additionally, time to occurrence of CV death and heart failure hospitalizations is illustrated along with cumulative failure rates. This information provides valuable insights into the efficacy of each treatment in managing heart failure patients.*
Structure (Sacubitril Valsartan Structure)
Sacubitril-valsartanl-figure-4.jpg (Sacubitril Valsartanl Figure 4)
The text provided contains data related to a clinical trial, including information about different subgroups based on age, gender, weight, race, region, medical history, and other categories. It also lists the percentages and numbers of individuals within each subgroup who were treated with Sacubitril and Valsartan or Enalapril. Additionally, the text mentions hazard ratios for the comparison between Sacubitril and Valsartan and Enalapril. The data seems to be part of a study evaluating the effectiveness of these medications for heart failure.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
